> Detailanzeige

Jones, Barbara; Holland, James F.; Glidewell, Oliver; Jacquillat, Claude; Weil, Marise; Pochedly, Carl; Sinks, Lucius; Chevalier, Louise; Maurer, Harold M.; Koch, Kjell; Falkson, Geoffrey; Patterson, Richard; Seligman, Barbara; Sartorius, Jurg; Kung, Faith; Haurani, Farid; Stuart, Marie; Burgert, E. Omer; Ruymann, Frederick; Sawitsky, Arthur; Forman, Edwin; Pluess, Hansjuerg; Truman, John; Hakami, Nasrollah

Optimal use of L‐asparaginase (NSC‐109229) in acute lymphocytic leukemia

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Optimal use of L‐asparaginase (NSC‐109229) in acute lymphocytic leukemia
  • Beteiligte: Jones, Barbara; Holland, James F.; Glidewell, Oliver; Jacquillat, Claude; Weil, Marise; Pochedly, Carl; Sinks, Lucius; Chevalier, Louise; Maurer, Harold M.; Koch, Kjell; Falkson, Geoffrey; Patterson, Richard; Seligman, Barbara; Sartorius, Jurg; Kung, Faith; Haurani, Farid; Stuart, Marie; Burgert, E. Omer; Ruymann, Frederick; Sawitsky, Arthur; Forman, Edwin; Pluess, Hansjuerg; Truman, John; Hakami, Nasrollah
  • Erschienen: Wiley, 1977
  • Erschienen in: Medical and Pediatric Oncology, 3 (1977) 4, Seite 387-400
  • Sprache: Englisch
  • DOI: 10.1002/mpo.2950030410
  • ISSN: 0098-1532; 1096-911X
  • Schlagwörter: Cancer Research ; Oncology ; Pediatrics, Perinatology and Child Health
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: AbstractBetween 1971 and 1974, 646 evaluable patients under 20 years of age with previously untreated acute lymphocytic leukemia were treated according to Cancer and Leukemia Group B (formerly Acute Leukemia Group B) Protocol 7111. On a random basis, they received a 10‐day course of 1,000 units/kg/day of L‐asparaginase before, during, or after a 3‐week course of vincristine and corticosteroid. A control group received vincristine and corticosteroid for 4 weeks but no asparaginase. The overall complete remission rate was 85%, which was not altered significantly by any of the induction variables. Patients who received asparaginase for 10 days subsequent to vincristine and corticosteroid had a significantly longer complete remission duration with an estimated median of 45 months, compared to 20 months for the group receiving no asparaginase and 27 months for the other 2 asparaginase regimens. The beneficial effect of asparaginase was noted, irrespective of which 1 of the 2 intensification and maintenance programs the patients received. The 5‐year projection indicates a complete remission rate of 50% for those patients receiving subsequent asparaginase as compared to 41% of those induced on other regimens in this study and thus is superior to the use of only vincristine and corticosteroid.